Which of the following is a counseling point for mepolizumab?

Mepolizumab is an interleukin-5 antagonist that is used to treat severe asthma and is approved for patients aged 6 years and older. This makes it a suitable treatment option for a younger age group compared to some other biologics which may have stricter age restrictions. The indication for patients greater than 6 years old allows clinicians to consider mepolizumab as an effective therapy for pediatric patients suffering from severe asthma, expanding the treatment options available for this population.

This age range is particularly relevant in asthma management since early intervention can help control symptoms, potentially leading to better long-term outcomes. By specifically targeting an interleukin involved in the allergic inflammatory response, mepolizumab helps to reduce exacerbations and overall asthma control.

The other options do not accurately reflect the characteristics of mepolizumab. It is not administered orally or intravenously; instead, it is given as a subcutaneous injection and not every four weeks for intravenous administration. Also, while it is approved for use in patients 6 years and older, it does not have a restriction limiting its use to those 18 years and older.